Get the Stockscreener App
25.73
2.35%
0.59
Pre-market:
25.85
0.12
+0.47%
Procept Biorobotics Corp stock is traded at $25.73, with a volume of 1.04M.
It is up +2.35% in the last 24 hours and down -0.23% over the past month.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
See More
Previous Close:
$25.14
Open:
$24.97
24h Volume:
1.04M
Relative Volume:
0.65
Market Cap:
$1.45B
Revenue:
$308.05M
Net Income/Loss:
$-95.57M
P/E Ratio:
-14.96
EPS:
-1.72
Net Cash Flow:
$-58.34M
1W Performance:
+9.68%
1M Performance:
-0.23%
6M Performance:
-25.89%
1Y Performance:
-51.48%
1-Day Range:
$24.80
$25.97
1-Week Range:
$23.54
$26.01
52-Week Range:
$19.35
$66.85
Procept Biorobotics Corp Stock (PRCT) Company Profile
Name
Procept Biorobotics Corp
Sector
Industry
Phone
(650) 232-9832
Address
150 BAYTECH DRIVE, SAN JOSE
Compare PRCT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRCT
Procept Biorobotics Corp
|
25.73 | 1.42B | 308.05M | -95.57M | -58.34M | -1.72 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Initiated | Robert W. Baird | Neutral |
| Feb-26-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-26-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-12-25 | Initiated | UBS | Buy |
| Dec-08-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-02-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-09-25 | Initiated | Stephens | Overweight |
| Jul-07-25 | Initiated | Oppenheimer | Perform |
| Dec-02-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Initiated | Jefferies | Hold |
| Aug-11-23 | Initiated | Piper Sandler | Overweight |
| May-31-23 | Initiated | William Blair | Outperform |
| Oct-31-22 | Initiated | BTIG Research | Neutral |
| Oct-25-22 | Initiated | Truist | Buy |
| Sep-02-22 | Initiated | Wells Fargo | Overweight |
| Jul-15-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Goldman | Neutral |
| Oct-11-21 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | SVB Leerink | Outperform |
View All
Procept Biorobotics Corp Stock (PRCT) Latest News
Wells Fargo lowers Procept BioRobotics target after weak Q4 performance - MSN
Assessing PROCEPT BioRobotics (PRCT) Valuation After Strong Q3 2025 Update And 2026 Outlook - Sahm
Chicago Capital LLC Has $37.47 Million Holdings in PROCEPT BioRobotics Corporation $PRCT - MarketBeat
PROCEPT BioRobotics (PRCT) price target decreased by 37.60% to 33.58 - MSN
PROCEPT BioRobotics (PRCT) Projected to Post Earnings on Thursday - MarketBeat
PROCEPT BioRobotics (PRCT) Is Up 7.5% After Raising 2026 Revenue Outlook And Sharpening Growth Focus - simplywall.st
PROCEPT BioRobotics (PRCT) Earnings Transcript - The Motley Fool
PROCEPT BioRobotics (PRCT) Financial Results Conference Transcript - Bitget
Baillie Gifford & Co. Purchases 157,147 Shares of PROCEPT BioRobotics Corporation $PRCT - MarketBeat
PROCEPT BioRobotics to Report First Quarter 2026 Financial Results on April 29, 2026 - 富途牛牛
PROCEPT BioRobotics (PRCT) strengthens its case with expanding system base - MSN
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026 - GlobeNewswire
PRCT Drops 8.6% as Uncertain Indicators and Soft Fundamentals Persist - Bitget
Morgan Stanley Maintains PROCEPT BioRobotics (PRCT) Overweight Recommendation - MSN
A Look At PROCEPT BioRobotics (PRCT) Valuation After New European Aquablation Guideline Upgrade - simplywall.st
Oppenheimer Upgrades PROCEPT BioRobotics (PRCT) - MSN
PRCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will Aquablation’s Strong EU Guideline Backing Reshape PROCEPT BioRobotics’ (PRCT) Long-Term Narrative? - Sahm
PROCEPT BioRobotics Corporation $PRCT Shares Acquired by SG Americas Securities LLC - MarketBeat
Prosight Management, LP's PROCEPT BioRobotics Corp(PRCT) Holding History - GuruFocus
PRCT Stock Price, Quote & Chart | PROCEPT BIOROBOTICS CORP (NASDAQ:PRCT) - ChartMill
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES - MarketScreener
Short Covering: Is PROCEPT BioRobotics Corporation a turnaround story2026 Patterns & Real-Time Buy Signal Alerts - baoquankhu1.vn
PROCEPT BioRobotics: An Undervalued Surgical Robotics Growth Story (NASDAQ:PRCT) - Seeking Alpha
Truist Lowers PT on PROCEPT BioRobotics Corporation (PRCT) to $50 From $64, Keeps a Buy Rating - MSN
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Rating of "Hold" by Brokerages - marketbeat.com
PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 6.6%Still a Buy? - MarketBeat
Vanguard Realigns Reporting; PROCEPT BioRobotics (PRCT) Beneficial Ownership 0% - Stock Titan
EAU Upgrade Puts Aquablation And PROCEPT BioRobotics In Focus - Yahoo Finance
PROCEPT BioRobotics (PRCT) Strengthens Its Case with Expanding System Base - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics CorporationPRCT - PR Newswire
PRCT: GUIDED $325.5M, HID PRICING HEADWIND -- LEVI & KORSINSKY, LLP INVESTIGATES - GlobeNewswire
How Investors May Respond To PROCEPT BioRobotics (PRCT) Winning Strong EAU Backing For Aquablation - simplywall.st
PROCEPT BioRobotics outlines $325.5M 2025 revenue target amid leadership transition and margin expansion - MSN
PROCEPT BioRobotics Corporation (PRCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
JPMorgan Chase & Co. Cuts Stake in PROCEPT BioRobotics Corporation $PRCT - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems - marketscreener.com
User - The Chronicle-Journal
Bronstein, Gewirtz & Grossman, LLC Is Investigating PROCEPT BioRobotics Corporation (PRCT) And Encourages Shareholders to Connect - ACCESS Newswire
A Look At PROCEPT BioRobotics (PRCT) Valuation After Aquablation Wins Strong European Guideline Backing - simplywall.st
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Chemed (CHE) and PROCEPT BioRobotics (PRCT) - The Globe and Mail
Europe's top urology guide strongly backs Aquablation for BPH - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PROCEPT BioRobotics Corporation (PRCT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Alaleh Nouri, EVP at Procept Biorobotics, sells $139k in PRCT stock - Investing.com Australia
Procept Biorobotics Corp Stock (PRCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):